Photodynamic Therapy in Glioma: A Survey on Metabolic Reprogramming and Therapeutic Resistance

www.surveyx.cn

Abstract

Photodynamic therapy (PDT) has emerged as a promising non-invasive treatment for gliomas, leveraging the interaction between photosensitizers, light, and molecular oxygen to produce cytotoxic reactive oxygen species (ROS) that selectively target tumor cells. Recent advancements in photosensitizer development, such as the incorporation of nanotechnology and third-generation photosensitizers, have enhanced PDT's efficacy by improving solubility, stability, and tumor-targeting capabilities. However, challenges such as limited light penetration, hypoxic tumor environments, and therapeutic resistance persist. The tumor microenvironment (TME) plays a crucial role in mediating resistance through metabolic reprogramming and immune evasion, necessitating strategies that target both tumor cells and the TME. Precision medicine offers a tailored approach, integrating metabolic profiling and advanced imaging techniques to optimize PDT protocols. The integration of PDT with other modalities, such as chemotherapy and immunotherapy, holds potential for synergistic effects, enhancing treatment outcomes. Furthermore, innovative technologies like quantum computing and nanotechnology are poised to refine photosensitizer performance and targeting efficiency. As research progresses, understanding the complex interplay between metabolic pathways and the TME will be critical in overcoming therapeutic resistance and improving glioma management. By leveraging these advancements, PDT could become a cornerstone in the personalized treatment of gliomas, offering improved precision and efficacy.

1 Introduction

1.1 Significance of Photodynamic Therapy in Glioma

Photodynamic therapy (PDT) represents a pivotal non-invasive approach for treating glioma, a common and aggressive primary malignant brain tumor in adults [1]. PDT operates through the interaction of a photosensitizer, light, and molecular oxygen, resulting in the production of cytotoxic reactive oxygen species that selectively destroy tumor cells while preserving adjacent healthy tissue [2]. This targeted mechanism is particularly vital in glioma due to its infiltrative characteristics, which complicate conventional treatment options [2]. Recent advancements, including the development of BODIPY derivatives, have improved PDT's therapeutic efficacy by enhancing excitation energy predictions and optimizing photosensitizer performance [3]. Furthermore, integrating advanced imaging techniques has augmented PDT's diagnostic and therapeutic effectiveness, facilitating more precise monitoring and treatment of gliomas [4]. The innovative use of serum proteins as nanothermometers also provides valuable insights into extracellular temperature dynamics, essential for understanding cellular metabolism and refining PDT protocols [5]. Ongoing research is expected to refine photosensitizers and explore combination therapies, addressing existing limitations and enhancing PDT's clinical relevance in glioma treatment.



Figure 1: chapter structure

1.2 Challenges of Metabolic Reprogramming and Therapeutic Resistance

Understanding the challenges of metabolic reprogramming and therapeutic resistance in glioma is crucial for recognizing the limitations of current treatment strategies and the necessity for innovative solutions [6]. Glioma cells exhibit significant metabolic plasticity, allowing them to adapt to the tumor microenvironment (TME), often characterized by hypoxia and nutrient scarcity [4]. This adaptability supports their survival and proliferation, contributing to resistance against various therapies, including PDT [1]. The capacity of glioma cells to modulate metabolic pathways, such as transitioning between glycolysis and oxidative phosphorylation, complicates therapeutic efforts [6].

Within this context, PDT encounters specific challenges; the efficacy of photosensitizers is often limited by inadequate distribution and light attenuation in tissues [5]. Additionally, the hypoxic glioma environment restricts oxygen availability, a critical element for generating reactive oxygen species necessary for effective PDT [6]. This limitation highlights the urgent need for improved photosensitizer designs and oxygenation strategies to enhance PDT outcomes.

The intricate interactions between photosensitizers and molecular oxygen further complicate the therapeutic landscape, influenced by quantum mechanical factors that affect reactive species generation [6]. Moreover, the challenge of delivering sufficient light to deep-seated tumors remains a significant barrier to the successful application of PDT [6].

Addressing these multifaceted challenges requires a comprehensive understanding of glioma cell metabolic adaptations and the complex interactions within the TME, shaped by both cancer cell

AI-generated, for reference only.

metabolism and their communication with surrounding stromal components. This knowledge is essential for identifying potential therapeutic targets and developing effective strategies to overcome treatment resistance associated with the TME [7, 8, 9, 10]. By surmounting these obstacles, it may be possible to enhance PDT efficacy and other therapeutic modalities, ultimately improving outcomes for glioma patients.The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Glioma and Its Pathogenesis

Gliomas, originating from glial cells, represent a diverse group of primary brain tumors known for rapid growth and poor prognosis, complicating cancer treatment due to their complex pathogenesis [2]. Isocitrate dehydrogenase (IDH) mutations significantly influence glioma biology, contributing to metabolic reprogramming that supports tumorigenesis [11]. The aggressive glioblastoma subtype is particularly challenging due to its cellular diversity, fostering treatment resistance and recurrence [1]. Gliomas' infiltrative properties hinder surgical resection and therapy, as they invade surrounding tissue. The tumor microenvironment (TME), characterized by hypoxia and immune suppression, plays a crucial role in glioma resilience against conventional treatments. Understanding glioma pathogenesis is vital for developing innovative therapeutic strategies to address tumor recurrence and metabolic reprogramming [1, 10].

2.2 Photodynamic Therapy (PDT)

Photodynamic therapy (PDT) utilizes photosensitizers (PSs), light, and molecular oxygen to produce reactive oxygen species (ROS), leading to targeted cell death [12]. Activation of PSs with specific light wavelengths results in localized cellular damage, benefiting gliomas due to their infiltrative nature [2]. Third-generation PSs like G-chlorin and M-chlorin enhance cancer cell targeting, optimizing therapeutic outcomes while minimizing healthy tissue damage [13]. The adoption of near-infrared (NIR) dyes enhances tissue penetration, addressing traditional fluorophore limitations in cancer imaging and therapy [14]. PDT's efficacy is further enhanced by combining it with modalities like chemotherapy, radiotherapy, and immunotherapy [15]. Functionalizing TiO2 nanoparticles with folic acid improves targeting specificity, amplifying PDT precision [16]. Despite its potential, PDT faces challenges such as limited light penetration and tumor hypoxia, which hinder ROS generation [17]. Novel PS designs and integration with immunotherapy are being explored to enhance clinical applicability [17]. The DUE method improves light intensity delivery, enhancing PDT efficacy in glioma treatment [18]. Ongoing research aims to optimize PS performance and integrate PDT with multimodal strategies to improve patient outcomes [3, 19].

2.3 Metabolic Reprogramming in Cancer

Metabolic reprogramming is a hallmark of cancer, enabling cells to alter metabolic pathways to support rapid proliferation and survival under stress [20]. This often involves a shift from oxidative phosphorylation to aerobic glycolysis, the Warburg effect, facilitating ATP generation and biosynthetic precursor production for tumor growth. In glioblastoma, increased glucose transporter GLUT3 enhances glucose uptake and glycolysis, aiding survival in low-glucose conditions [21]. Glutamine serves as a crucial alternative carbon source for anabolic processes and redox balance, especially in nutrient-deprived environments [22]. Targeting glutaminolysis is a promising therapeutic strategy due to its role in cancer metabolism. Lactate, once considered a metabolic byproduct, is now recognized for its role in lactylation, influencing gene expression and immune responses in the TME [23]. This highlights the relationship between metabolic pathways and epigenetic regulation in cancer. The metabolic interplay between cancer and immune cells is crucial for immunotherapy, as resource competition in the TME can modulate immune function and facilitate immune evasion [24]. Viral infections also induce metabolic changes in host cells, potentially promoting oncogenesis [25], while circular RNAs (circRNAs) regulate key metabolic processes, influencing glycolysis and oxidative respiration [26]. Understanding metabolic reprogramming in cancer is essential for identifying therapeutic targets and developing strategies against resistance in tumor progression and metastasis [20, 27, 10, 28].

2.4 Tumor Microenvironment (TME)

The tumor microenvironment (TME) comprises cancer cells, stromal cells, immune cells, extracellular matrix components, and signaling molecules, influencing tumor behavior and therapeutic resistance. Recent studies emphasize metabolic interactions within the TME, revealing their role in tumor evolution and treatment responses [8, 9, 29]. Cancer-associated fibroblasts (CAFs) significantly impact tumor growth by secreting growth factors and remodeling the extracellular matrix [30]. These interactions support tumor cell proliferation and modulate immune function, often leading to immune suppression and evasion [8]. The metabolic interplay between CAFs and tumor cells illustrates the TME's role in sustaining cancer metabolism, with tumor-secreted metabolites affecting immune regulation and cancer cell plasticity [8]. Metabolic adaptations within the TME enable cancer cells to thrive under hypoxic and nutrient-deprived conditions, involving shifts in glycolysis and fatty acid metabolism critical for energy homeostasis [31]. This metabolic reprogramming promotes resistance to therapies, including PDT [4]. Exosome-mediated communication within the TME underscores its complexity, facilitating molecular exchanges between cancer, stromal, and immune cells, influencing tumor progression and treatment outcomes [7]. These vesicles carry proteins, lipids, and nucleic acids that modulate recipient cell behavior, contributing to a pro-tumorigenic environment and enhancing resistance to conventional treatments [7]. Understanding TME interactions is essential for developing effective therapeutic strategies targeting both tumor cells and their supportive microenvironment, as these interactions significantly impact tumor progression and treatment efficacy [7, 30, 9, 8, 29].

2.5 Precision Medicine in Glioma Treatment

Precision medicine transforms glioma treatment by customizing strategies based on genetic, epigenetic, and metabolic tumor profiles, enhancing treatment efficacy and minimizing adverse effects [6]. Next-generation sequencing and molecular profiling identify actionable mutations and biomarkers in gliomas, facilitating targeted therapies addressing specific oncogenic drivers [1]. IDH mutations, linked to distinct metabolic reprogramming, offer targets for precision interventions [11]. Targeted therapies inhibiting mutant IDH enzymes aim to disrupt altered metabolic pathways and impede tumor growth [11]. Precision medicine integrates an understanding of tumor heterogeneity and the TME to devise combination therapies addressing multiple tumor biology aspects [4]. By targeting both cancer cells and their supportive microenvironment, precision strategies aim to overcome resistance and enhance treatment efficacy [6]. Precision medicine also involves novel imaging techniques and computational models to predict treatment responses and optimize regimens [2]. These advancements enable real-time monitoring of tumor dynamics and treatment efficacy assessment, facilitating adaptive strategies based on patient-specific responses [4]. Precision medicine holds promise for transforming glioma treatment by providing personalized options informed by molecular and metabolic tumor characteristics. As research progresses, integrating precision medicine with technologies like glioma-on-chip models and genomic insights is expected to improve management and outcomes for glioma patients, particularly in addressing resistance and enhancing survival rates and quality of life [4, 1, 10].

3 Photodynamic Therapy in Glioma

Category	Feature	Method
Principles and Mechanisms of Photodynamic Therapy	Light and Imaging Techniques Diagnostic and Monitoring Tools	MCM[32] Serum-ABNT[5]
Advancements in Photosensitizer Development	Quantum Simulation Methods	ADAPT[3]
Challenges and Limitations	Biological Delivery Challenges	TPE-red-PEG-RGD[33], IPRT[19]
Integration with Other Therapies	Therapeutic Synergy	DUE[18]

Table 1: This table provides a comprehensive summary of the key methods and tools associated with photodynamic therapy (PDT) in glioma treatment. It categorizes these methods into four main areas: principles and mechanisms of PDT, advancements in photosensitizer development, challenges and limitations, and integration with other therapies. The table also highlights specific techniques and innovations in each category, emphasizing their significance in enhancing the efficacy and application of PDT in clinical settings.

To fully appreciate the significance of photodynamic therapy (PDT) in the context of glioma treatment, it is essential to first understand the underlying principles and mechanisms that govern this innovative therapeutic approach. The intricate interplay between photosensitizers, light, and molecular oxygen forms the basis of PDT, enabling targeted cellular destruction through the generation of reactive oxygen species (ROS). This foundational knowledge provides the necessary framework for exploring the specific mechanisms by which PDT exerts its effects on glioma cells, as discussed in the following subsection. Table 2 presents an organized overview of the various methodologies and innovations in photodynamic therapy (PDT) relevant to glioma treatment, detailing the principles, advancements, challenges, and potential therapeutic integrations. **??** illustrates the hierarchical structure of PDT in glioma treatment, highlighting key principles, advancements, challenges, and integration with other therapies. This figure categorizes the fundamental components and mechanisms of PDT, the evolution of photosensitizers, inherent challenges, and the potential for combining PDT with other therapeutic modalities to enhance treatment efficacy. By examining this visual representation, readers can better grasp the multifaceted nature of PDT and its role in glioma treatment.

3.1 Principles and Mechanisms of Photodynamic Therapy

Photodynamic therapy (PDT) is predicated on the interaction between photosensitizers, light, and molecular oxygen to generate reactive oxygen species (ROS), which are critical for inducing cytotoxic effects in targeted cancer cells [34]. The fundamental mechanism involves the absorption of light by the photosensitizer, which transitions to an excited state and subsequently transfers energy to molecular oxygen, producing ROS that mediate cellular damage and apoptosis [34]. This process is highly selective, as the photosensitizer accumulates preferentially in tumor tissues, thereby sparing surrounding healthy cells and minimizing collateral damage.

The effectiveness of PDT in glioma treatment is enhanced by the precise targeting of mitochondrial proteins, such as cytochrome c oxidase (COX), which plays a pivotal role in cellular respiration and energy production [35]. By disrupting mitochondrial function, PDT can induce apoptosis and inhibit tumor growth, offering a potent therapeutic strategy against gliomas, which are notoriously resistant to conventional therapies.

One of the challenges in PDT is the delivery of adequate light to deep-seated tumors within the brain. The Digital Ultrasonically Encoded (DUE) optical focusing technique addresses this limitation by using focused ultrasound as a virtual guide star to optimize the phase of incident light in scattering media, thereby enhancing light delivery to target regions [18]. This approach improves the efficacy of PDT by ensuring sufficient light penetration and activation of the photosensitizer within the tumor.

Additionally, the integration of diagnostic modalities such as Raman spectroscopy with PDT offers a theranostic platform that combines therapeutic and diagnostic capabilities without interference [19]. This complementary approach allows for real-time monitoring of treatment efficacy and tumor response, facilitating adaptive therapeutic strategies.

Furthermore, the application of advanced imaging techniques, such as multiscale super-resolution magnetic resonance imaging, enhances the diagnostic utility of PDT by providing detailed visualization of tumor characteristics and treatment response [32]. The ability to conditionally adapt to various input scenarios and tune image sharpness improves the overall effectiveness of PDT in clinical settings.

The use of Serum-Anisotropy Based Nanothermometer (Serum-ABNT) provides accurate temperature readings within the tumor microenvironment, which is crucial for optimizing PDT protocols and enhancing treatment efficacy [5]. By monitoring extracellular temperature dynamics, clinicians can adjust PDT parameters to maximize ROS generation and therapeutic outcomes.

The principles and mechanisms underlying photodynamic therapy (PDT) highlight its significant promise as a targeted and effective treatment for gliomas. This potential is bolstered by recent advancements in the development of novel photosensitizers, innovative light delivery techniques, and enhanced diagnostic imaging methods. These advancements aim to address existing challenges associated with PDT, such as limited tumor selectivity and light penetration depth, ultimately leading to improved patient outcomes and broader clinical applications. Furthermore, the integration of nanotechnology into PDT is enhancing targeting efficiency and solubility of photosensitizers, paving the way for more effective therapeutic strategies. [33, 15, 36, 12, 37]

As shown in Figure 2, Photodynamic Therapy (PDT) represents a promising approach in the treatment of glioma, leveraging the principles and mechanisms of light-induced chemical reactions to



(a) Light-Driven Bacterial Oxidation[37]

(b) Targeted Drug Delivery Strategies for Cancer[12]

(c) Microscopic Images of Cell Structures[35]

Figure 2: Examples of Principles and Mechanisms of Photodynamic Therapy

target cancerous cells. This therapeutic strategy involves the use of photosensitizing agents that, upon activation by a specific wavelength of light, produce reactive oxygen species (ROS) capable of inducing cellular damage and apoptosis in tumor tissues. The example provided illustrates various aspects of PDT, including light-driven bacterial oxidation, targeted drug delivery strategies for cancer, and microscopic images of cell structures. The light-driven bacterial oxidation image depicts the fundamental process of energy conversion, where light excites bacterial cells to produce ROS, highlighting the core mechanism of PDT. In contrast, the targeted drug delivery strategies image outlines innovative methods for directing therapeutic agents specifically to cancer cells, enhancing the efficacy of PDT. Lastly, the microscopic images provide a visual representation of cellular structures at the electron microscope level, offering insight into the subcellular targets of PDT and the potential for precision in treatment. Together, these images underscore the multifaceted nature of photodynamic therapy and its potential applications in glioma treatment. [**?**]<divstyle=0,niculescu2021photodynamic,boersch2010targetingcytochromecoxidase)

3.2 Advancements in Photosensitizer Development

Recent advancements in the development of photosensitizers have significantly contributed to the enhancement of photodynamic therapy (PDT) efficacy, particularly in the treatment of gliomas. The evolution of photosensitizers is categorized into distinct generations, each characterized by improvements in chemical properties and therapeutic performance. First-generation photosensitizers, such as hematoporphyrin derivatives, laid the groundwork for PDT but were limited by issues such as prolonged skin photosensitivity and suboptimal tissue penetration [12]. The advent of second-generation photosensitizers introduced synthetic compounds with improved photophysical properties, offering greater selectivity and reduced side effects [12].

The current frontier in photosensitizer development is marked by third-generation photosensitizers, which leverage nanotechnology to enhance therapeutic outcomes. These photosensitizers incorporate nanocarriers that improve solubility, stability, and tumor-targeting capabilities, thereby optimizing the delivery and activation of the therapeutic agent within the tumor microenvironment [12]. The integration of nanotechnology has also facilitated the development of highly photostable, water-soluble dyes, such as xanthene derivatives, which exhibit significant fluorescence enhancements. These properties not only improve imaging resolution but also enhance the therapeutic efficacy of PDT by enabling precise localization and destruction of tumor cells [14].

Moreover, advancements in quantum computing techniques, such as the ADAPT method, have introduced state-specific approaches that significantly reduce the circuit depth required for implementation on near-term quantum devices. This innovation enhances the efficacy of photosensitizers by allowing for more accurate calculations of excitation energies, thereby optimizing photosensitizer performance and ROS generation [3].

A notable development in the field is the introduction of aggregation-induced emission (AIE) luminogens, which address the limitations of traditional photosensitizers. AIE luminogens enhance fluorescence emission in nano-aggregation states, providing a robust solution to the challenges of photobleaching and limited fluorescence in biological environments [33]. These advancements underscore the potential of AIE luminogens to improve both the diagnostic and therapeutic aspects of PDT.

Additionally, the selective targeting of mitochondrial proteins, such as cytochrome c oxidase (COX), represents a strategic approach to enhancing PDT efficacy. By focusing on COX, which is integral to cellular respiration, PDT can more effectively induce apoptosis in cancer cells, offering a promising avenue for improving treatment outcomes [35].

These advancements in photosensitizer development highlight the ongoing efforts to refine PDT as a cancer treatment modality, with a focus on improving selectivity, reducing side effects, and enhancing overall therapeutic efficacy. As ongoing research progresses, the incorporation of cutting-edge technologies is anticipated to significantly enhance the effectiveness of photodynamic therapy (PDT) in clinical settings, particularly for difficult-to-treat malignancies such as gliomas. These advancements aim to address current limitations of PDT, including issues with tumor selectivity and light penetration, while also leveraging immune responses triggered by the therapy to improve antitumor efficacy. Notably, innovations such as next-generation photosensitizers designed to exploit the Warburg effect and combination therapies integrating PDT with immunotherapy are expected to broaden the therapeutic applications of PDT in oncology.

As illustrated in Figure 3, the figure encapsulates these recent advancements in photosensitizer development for photodynamic therapy, highlighting the evolution through different generations, the integration of innovative technologies, and the strategic targeting approaches to enhance therapeutic efficacy. [15, 13, 36, 19]



Figure 3: This figure illustrates the recent advancements in photosensitizer development for photodynamic therapy, highlighting the evolution through different generations, the integration of innovative technologies, and the strategic targeting approaches to enhance therapeutic efficacy.

3.3 Challenges and Limitations

Photodynamic therapy (PDT) encounters several inherent challenges and limitations that hinder its efficacy and broader clinical application, particularly in the treatment of gliomas. A significant challenge in PDT is the aggregation-caused quenching effect observed in traditional photosensitizers, which severely limits their optical imaging performance and reduces the effectiveness of the therapy [33]. This quenching effect results in diminished fluorescence emission and compromised therapeutic outcomes, necessitating the development of novel photosensitizers that can overcome these limitations.

The effective delivery of photosensitizers to tumor sites is significantly hindered by biological barriers, particularly the blood-brain barrier in gliomas, which limits the penetration and distribution of therapeutic agents. This barrier complicates the application of photodynamic therapy (PDT), a minimally invasive treatment that relies on the generation of reactive oxygen species (ROS) to induce tumor cell death and potentially stimulate an immune response. Overcoming these barriers is crucial for enhancing the efficacy of PDT in treating resistant tumors like glioblastoma, where conventional therapies often fail to prevent recurrence. [36, 1, 15, 17]. This limitation necessitates high levels of reactive oxygen species (ROS) generation to achieve therapeutic efficacy, which can be challenging to maintain consistently across different tumor environments. The incomplete understanding of PDT mechanisms and the variability in photosensitizer distribution further contribute to the inconsistent therapeutic outcomes observed in clinical settings.

The penetration depth of light is another critical limitation, as the effectiveness of PDT is highly contingent on the ability of light to reach and activate photosensitizers within deep-seated tumors [17]. This challenge is exacerbated by the hypoxic nature of tumors, which impairs ROS generation due to limited oxygen availability, thereby reducing PDT efficacy [17]. The varying effectiveness of different photosensitizers and the need for better targeting strategies underscore the importance of optimizing treatment protocols to enhance therapeutic outcomes [15].

Despite advancements in photosensitizer development, such as the introduction of G-chlorin and M-chlorin, challenges remain regarding their hydrophilicity, which affects solubility and distribution in biological systems [13]. Achieving the desired selectivity and specificity for cancer cells continues to be a formidable task, compounded by the complexity of synthesizing and modifying these dyes [14].

Additionally, the optimization of PDT protocols is constrained by computational challenges, as the exponential growth of computational requirements with increasing dataset sizes renders current methods impractical [38]. While the Digital Ultrasonically Encoded (DUE) method shows promise in enhancing light delivery, its practical applications are limited by the lengthy optimization time required due to slow detection processes [18].

Moreover, the insufficient sensitivity of existing imaging techniques to localize photosensitizers such as Pt(II)-TMPyP within mitochondria during PDT poses a limitation, as precise localization is crucial for maximizing therapeutic efficacy [35]. However, the integration of diagnostic modalities such as Raman spectroscopy with PDT offers a promising theranostic platform that combines therapeutic and diagnostic capabilities without the trade-offs associated with nanoparticle targeting, thereby reducing toxicity and enhancing treatment specificity [19].

To fully harness the therapeutic potential of photodynamic therapy (PDT) for glioma treatment, it is crucial to address the complex challenges that currently hinder its effectiveness. This requires ongoing research and innovation in several key areas, including the development of advanced photosensitizers that enhance reactive oxygen species (ROS) production, the refinement of light delivery techniques to ensure optimal tumor targeting, and the establishment of improved treatment protocols that can stimulate robust antitumor immune responses. By focusing on these aspects, we can significantly enhance clinical outcomes and broaden the applicability of PDT in cancer therapy. [37, 36]

3.4 Integration with Other Therapies

Integrating photodynamic therapy (PDT) with other therapeutic modalities presents a promising strategy for enhancing treatment outcomes in glioma management. The combination of PDT with conventional treatments such as chemotherapy and radiotherapy can potentially overcome the limitations associated with each modality when used in isolation. Chemotherapy, for instance, can sensitize tumor cells to PDT by disrupting cellular repair mechanisms, thereby enhancing the cytotoxic effects of reactive oxygen species (ROS) generated during PDT [17]. Similarly, radiotherapy can complement PDT by inducing DNA damage and promoting apoptosis in tumor cells, thereby augmenting the overall therapeutic efficacy.

Innovative approaches also involve the use of targeted therapies that focus on specific molecular pathways implicated in tumor growth and survival. The use of cationic and lipophilic porphyrins that bind to mitochondrial cytochrome c oxidase (COX) exemplifies a targeted approach that can be integrated with PDT to induce cell death upon light activation [35]. This strategy leverages the preferential accumulation of photosensitizers in mitochondria, thereby enhancing the selectivity and potency of PDT-induced cytotoxicity.

Furthermore, the integration of PDT with emerging modalities such as immunotherapy and gene therapy holds significant potential for improving treatment outcomes. Immunotherapy, which aims to modulate the immune system to recognize and attack tumor cells, can be synergistically combined with PDT to enhance immune responses and promote tumor regression. PDT-induced tumor cell death can release tumor antigens, thereby facilitating the activation of immune cells and enhancing the efficacy of immunotherapeutic interventions [17].

The development of advanced targeting strategies and improvements in photosensitizer efficacy are crucial for optimizing the integration of PDT with other therapies. Future research should focus on enhancing algorithm speed through faster detection methods and spatial light modulators, which could broaden the applications of PDT in areas such as phototherapy and optogenetics [18]. These advancements will enable more precise and effective targeting of tumor cells, thereby maximizing therapeutic benefits while minimizing off-target effects.

The integration of photodynamic therapy (PDT) with other therapeutic modalities offers a comprehensive and multifaceted strategy for addressing the complexities of glioma treatment. PDT leverages the interaction between light and photosensitizers to generate reactive oxygen species (ROS), which can induce tumor cell death, disrupt tumor vasculature, and potentially initiate an immune response against the tumor. By combining PDT with advancements in nanotechnology and immunotherapy, researchers aim to enhance targeting efficiency, improve treatment outcomes, and overcome existing limitations such as light penetration depth and tumor selectivity. This synergistic approach not only broadens the therapeutic potential of PDT but also addresses the multifactorial challenges associated with glioma management. [15, 36, 12, 37, 19]. By combining the strengths of different therapies, it is possible to enhance treatment efficacy, overcome resistance mechanisms, and improve patient outcomes in the management of gliomas.

Feature	Principles and Mechanisms of Photodynamic Therapy	Advancements in Photosensitizer Development	Challenges and Limitations
Mechanism	Ros Generation	Nanotechnology-enhanced	Ros Production
Challenges	Light Delivery	Quenching Effect	Blood-brain Barrier
Integration Potential	Real-time Monitoring	Enhanced Imaging	Improved Protocols

Table 2: This table provides a comparative analysis of the methodologies and innovations in photodynamic therapy (PDT) relevant to glioma treatment. It outlines the principles and mechanisms of PDT, advancements in photosensitizer development, and the challenges and limitations encountered, along with the potential for therapeutic integration. This comprehensive overview highlights the multifaceted nature of PDT and its role in enhancing glioma treatment strategies.

4 Metabolic Reprogramming in Glioma

Exploring glioma biology necessitates understanding metabolic reprogramming as a key element influencing tumor behavior and therapeutic responses. This section examines the mechanisms underpinning metabolic alterations in glioma cells, elucidating the biochemical pathways and cellular adaptations characterizing this malignancy. By examining these mechanisms, we gain insights into the challenges posed by glioma and identify potential therapeutic targets to enhance treatment efficacy.

4.1 Mechanisms of Metabolic Reprogramming

Metabolic reprogramming in glioma cells, a hallmark of tumor progression, enables adaptation to the tumor microenvironment and sustains proliferation. This reprogramming involves a shift from oxidative phosphorylation to aerobic glycolysis, known as the Warburg effect, facilitating rapid ATP production and biosynthetic precursor generation essential for growth [10]. The metabolic shift enhances cytotoxicity and immunogenic cell death through photosensitizer accumulation [13]. Disrupting mitochondrial cytochrome c oxidase (COX) to inhibit ATP synthesis remains challenging yet crucial for inducing cancer cell death [35].

Isocitrate dehydrogenase (IDH) mutations in gliomas illustrate the complex relationship between metabolic alterations and tumor biology. These mutations produce 2-hydroxyglutarate (2-HG), an oncometabolite disrupting metabolism and epigenetic regulation, contributing to oncogenesis [11]. 2-HG accumulation creates a metabolic vulnerability that could enhance therapeutic outcomes.

Lactate, traditionally seen as a byproduct, emerges as a critical metabolite influencing tumor progression through histone lactylation, linking metabolism with gene expression and facilitating glioma cell adaptation [23]. The interplay between metabolic pathways and epigenetic changes underscores metabolic reprogramming complexity in gliomas.

The tumor microenvironment significantly influences metabolic reprogramming, with immune cells like macrophages exhibiting distinct metabolic profiles affecting tumor dynamics. M1 macrophages, associated with pro-inflammatory responses, show enhanced glycolysis, while M2 macrophages, linked to anti-inflammatory and tumor-promoting activities, exhibit decreased glycolytic activity [31]. This metabolic dichotomy highlights potential therapeutic strategies exploiting metabolic dependencies of tumor and immune cells.

Challenges include nutrient depletion, such as glucose and amino acids, in the tumor microenvironment, limiting tumor-specific immune cell proliferation and function [39]. Exosomes provide insights into metabolic interactions for new therapeutic strategies [7]. TPE-red-PEG-RGD nanoparticles leverage AIE luminogens' properties for high fluorescence and ROS generation efficiency in aggregated forms [33].

Computational models and evolutionary game theory provide a framework for understanding glioma cells' adaptive strategies to optimize metabolic pathways under environmental pressures [38]. These insights are crucial for identifying novel therapeutic targets and developing strategies to disrupt metabolic adaptations underpinning glioma growth and treatment resistance. Accurate extracellular temperature measurements provide insights into metabolic reprogramming essential for therapeutic strategies [5].

Figure 4 illustrates the mechanisms of metabolic reprogramming in gliomas, highlighting key metabolic pathways, the influence of the tumor microenvironment, and potential therapeutic strategies. This figure emphasizes the Warburg effect, IDH mutations, and lactate's role in metabolic pathways, while also exploring the impact of immune cells, nutrient depletion, and exosome interactions within the tumor microenvironment. Additionally, it outlines therapeutic strategies involving photosensitizers, targeting cytochrome C oxidase, and computational models for optimizing treatment approaches. These examples underscore metabolic reprogramming's complexity and significance in glioma, providing a foundation for future research and therapeutic development [24, 31, 21].



Figure 4: This figure illustrates the mechanisms of metabolic reprogramming in gliomas, highlighting key metabolic pathways, the influence of the tumor microenvironment, and potential therapeutic strategies. It emphasizes the Warburg effect, IDH mutations, and lactate's role in metabolic pathways, while also exploring the impact of immune cells, nutrient depletion, and exosome interactions within the tumor microenvironment. Additionally, it outlines therapeutic strategies involving photosensitizers, targeting cytochrome C oxidase, and computational models for optimizing treatment approaches.

4.2 Metabolic Pathways and Therapeutic Targeting

Exploring metabolic pathways in glioma provides insights into potential therapeutic targets to disrupt tumor growth. Glioma metabolism relies on glutamine, utilized differently by immune cells in the tumor microenvironment. M1 macrophages use glutamine for pro-inflammatory responses, while M2 macrophages rely on it for anti-inflammatory functions, highlighting metabolic dichotomy [31]. This differential glutamine utilization presents a therapeutic opportunity to modulate macrophage activity and enhance anti-tumor immunity.

As illustrated in Figure 5, which depicts the key metabolic pathways and therapeutic targeting strategies in glioma treatment, targeting mitochondrial proteins, particularly cytochrome c oxidase (COX), represents a promising therapeutic avenue. The binding of Pt(II)-TMPyP to COX, demonstrated through time-resolved phosphorescence measurements, underscores the potential to disrupt cellular respiration and induce apoptosis in glioma cells [35]. This approach aligns with broader strategies targeting cancer cell metabolic vulnerabilities to impair survival mechanisms.

Advancements in xanthene-based dye development enhance their photophysical properties, making them valuable for cancer imaging and photodynamic therapy (PDT) [14]. These dyes, modified for improved stability and targeting, offer dual diagnostic imaging and therapeutic efficacy, enhancing metabolic targeting precision in glioma treatment.

Circular RNAs (circRNAs) in cancer metabolism highlight potential novel therapeutic strategies. CircRNAs modulate key metabolic pathways, acting as potential biomarkers and therapeutic targets in cancer treatment [26]. Their involvement in regulating metabolic processes provides an additional complexity layer and opportunity for glioma therapy intervention.

Accurate excitation energy calculation for BODIPY derivatives, facilitated by advanced quantum computing techniques, is crucial for understanding their metabolic pathway role and optimizing therapeutic targeting in glioma treatment [3]. These insights refine photosensizer selection and application in PDT, enhancing treatment efficacy.

Integrating folic acid-functionalized TiO2 nanoparticles demonstrates improved stability and targeting capabilities, offering a promising approach to enhance therapeutic agent delivery and effectiveness in glioma [16]. This functionalization exemplifies targeted nanoparticle delivery systems' potential to overcome biological barriers and achieve selective tumor targeting.

Future research should focus on improving photosensizer targeting and expanding integrated diagnostic and therapeutic modalities, such as Raman spectroscopy, to enhance metabolic targeting precision and effectiveness in glioma and other cancers [19]. Leveraging these advancements can develop more effective strategies for disrupting metabolic pathways underpinning glioma growth and resistance, ultimately improving patient outcomes.



Figure 5: This figure illustrates the key metabolic pathways and therapeutic targeting strategies in glioma treatment, including glutamine utilization by macrophages, mitochondrial targeting through cytochrome c oxidase inhibition, and advanced therapeutic approaches involving xanthene dyes, circular RNAs, and folic acid-functionalized nanoparticles.

4.3 Epigenetic and Metabolic Interactions

The interplay between epigenetic changes and metabolic reprogramming is crucial for glioma progression, influencing tumor behavior and therapeutic outcomes. Metabolic alterations in glioma cells are pivotal drivers of epigenetic modifications, impacting tumor progression and treatment response [40]. These changes alter key metabolites' availability, serving as substrates or cofactors for epigenetic enzymes, modulating gene expression patterns crucial for tumor growth and survival.

Metabolism influences epigenetics through histone modifications and DNA methylation regulation. Oncometabolite accumulation, like 2-hydroxyglutarate (2-HG) from mutant isocitrate dehydrogenase (IDH), inhibits -ketoglutarate-dependent dioxygenases involved in demethylation, leading to epigenetic changes promoting oncogenesis [40]. This highlights the intricate relationship between metabolic reprogramming and epigenetic regulation in glioma, where metabolic byproducts act as epigenetic modifiers, altering tumor progression gene expression.

The tumor microenvironment profoundly influences glioma cells' metabolic and epigenetic landscape. Hypoxic conditions induce metabolic shifts affecting the epigenetic state, complicating therapeutic interventions [4]. These factors stabilize hypoxia-inducible factors (HIFs), interacting with epigenetic regulators, influencing gene expression, and promoting tumor adaptation to hypoxic stress.

Current research advances in glioma biology modeling provide accurate tumor behavior representation and enable testing therapeutic strategies targeting metabolic and epigenetic vulnerabilities [4]. Integrating these insights can develop targeted therapies disrupting the metabolic-epigenetic axis, offering new avenues for overcoming resistance and improving treatment efficacy in glioma patients.

Dynamic interactions between metabolic reprogramming and epigenetic changes underscore glioma biology complexity and highlight the need for comprehensive therapeutic approaches addressing both aspects. As research evolves, integrating metabolic and epigenetic insights is increasingly recognized as promising for developing more effective and personalized treatment strategies. This approach acknowledges glioma cells' utilization of various metabolic pathways—beyond glucose—leveraging amino acids and fatty acids for energy and cellular maintenance. Understanding the genomic landscape and recurrence-initiating stem-like cancer (RISC) cells' presence, displaying inherent and adaptive therapy resistance, underscores targeting specific molecular alterations to combat tumor recurrence. By combining metabolic and epigenetic insights, researchers aim to tailor treatments addressing individual gliomas' unique characteristics, ultimately improving patient outcomes [1, 10].

5 Therapeutic Resistance in Glioma

Therapeutic resistance in glioma is a significant challenge, driven by complex interactions within the tumor microenvironment (TME) where tumor and immune cells compete for resources, affecting tumor growth and treatment response. This section explores the dynamics of metabolic competition and its implications for therapeutic strategies.

5.1 Metabolic Competition and Resistance

Metabolic competition in the TME is a key factor in glioma therapeutic resistance, as tumor and immune cells vie for nutrients, leading to immune suppression and reduced treatment efficacy [24]. The TME's adaptability complicates therapeutic strategies, enabling tumor cells to evade treatments [9]. Macrophage polarization, influenced by metabolic pathways, plays a crucial role, with M1 and M2 phenotypes impacting tumor progression and resistance [31]. Lactate, a glycolysis byproduct, acts as a metabolic substrate and signaling molecule, enhancing immune suppression and cancer cell survival, thereby contributing to resistance [23, 29].

Biochemical assays and genetic manipulation reveal how metabolic changes affect chromatin dynamics and resistance [40]. Current models, such as 2D cultures and animal models, often fail to replicate human glioma pathophysiology, necessitating innovative modeling methods [4]. Limitations in quantum chemistry methods like TDDFT and EOM-CCSD in predicting excitation energies highlight challenges in addressing resistance [3]. Advanced computational models, including evolutionary game theory, promise enhanced study of metabolic competition by reducing computational time and improving scalability [38].

A comprehensive understanding of TME interactions is crucial for developing targeted strategies to overcome resistance mechanisms, addressing tumor recurrence, and improving glioma patient outcomes [9, 1].

5.2 Tumor Microenvironment and Immune Evasion

The TME plays a pivotal role in immune evasion and therapy resistance in glioma, significantly impacting treatment efficacy, including photodynamic therapy (PDT) [4]. Cancer-associated fibroblasts (CAFs) modulate immune cell function by secreting cytokines and growth factors, promoting a pro-tumorigenic environment [30]. This interaction often polarizes immune cells towards an immunosuppressive phenotype, such as M2 macrophages, which support tumor growth while inhibiting anti-tumor responses [31].

Metabolic reprogramming within the TME exacerbates immune evasion, with enhanced glycolytic activity in tumor cells leading to lactate accumulation, suppressing effector immune cells like T cells and NK cells [23]. This metabolic competition fosters an environment conducive to tumor survival and resistance [24]. Exosomes mediate immune evasion by carrying immunosuppressive molecules, altering immune cell behavior and establishing an immunosuppressive microenvironment [7].

Hypoxia within the TME stabilizes hypoxia-inducible factors (HIFs), modifying gene expression involved in immune regulation and recruiting immunosuppressive cells [4]. This hypoxic environment supports tumor cell survival and diminishes the effectiveness of ROS-dependent treatments like PDT.

Understanding TME interactions is essential for developing strategies to overcome immune evasion and enhance glioma treatment efficacy. By targeting TME components and interactions that promote immune suppression, it may be possible to improve existing therapies and devise innovative strategies addressing resistance and immune evasion in glioma, focusing on adaptive resistance driven by genetic alterations and TME influences. This dual focus could lead to more personalized interventions against glioblastoma, characterized by high recurrence and poor prognosis [1, 8, 9].

5.3 IDH Mutations and Adaptive Resistance

Isocitrate dehydrogenase (IDH) mutations, characteristic of some gliomas, significantly contribute to adaptive resistance, complicating treatment strategies [11]. These mutations produce the oncometabolite 2-hydroxyglutarate (2-HG), altering glioma metabolism and epigenetic landscapes. 2-HG accumulation inhibits -ketoglutarate-dependent dioxygenases, leading to epigenetic changes that promote tumorigenesis and provide a survival advantage under therapeutic pressure [11].

IDH mutations drive metabolic reprogramming that supports glioma growth and enhances resistance to conventional therapies, allowing adaptation to hostile TME conditions like hypoxia and nutrient deprivation [11]. Future research should focus on developing therapies targeting the unique vulnerabilities of IDH-mutant gliomas, particularly by addressing metabolic pathways altered by 2-HG and understanding adaptive resistance in resistant glioma stem cells (RISC) [1]. Elucidating the molecular basis of IDH mutation-driven resistance may lead to more effective therapeutic strategies, improving outcomes for patients with IDH-mutant gliomas.

6 Precision Medicine and Targeted Interventions

Precision medicine has emerged as a pivotal approach in addressing complex malignancies like gliomas, emphasizing the tailoring of treatment strategies to the unique biological characteristics of individual tumors. This involves understanding the tumor microenvironment (TME) and its influence on therapeutic resistance and efficacy. By dissecting interactions within the TME, such as those involving cancer-associated fibroblasts and metabolic dynamics, treatment outcomes can be improved while minimizing adverse effects [30, 1, 9, 8, 29]. The application of photodynamic therapy (PDT) within precision medicine exemplifies the potential of advanced technologies to enhance glioma patient outcomes.

6.1 Integration of Photodynamic Therapy with Precision Medicine

Integrating photodynamic therapy (PDT) with precision medicine represents a significant advancement in glioma treatment, combining PDT's specificity with personalized strategies to boost efficacy. This involves customizing treatment based on each tumor's genetic, metabolic, and molecular profiles, thus optimizing outcomes and reducing side effects [4]. A key focus is on targeting metabolic pathways such as the upregulated glucose transporter GLUT3 in glioblastoma cells, which is crucial for metabolic reprogramming and therapy resistance. Inhibiting GLUT3 could enhance PDT effectiveness by disrupting the tumor's metabolic adaptations [21, 31].

Advances in quantum mechanical methods, such as the ADAPT technique, improve understanding of PDT interactions by enabling precise calculations of excitation energies, which are vital for designing effective photosensitizers. Techniques like ADAPT-VQE and UCCSD-VQE provide reliable predictions, surpassing traditional methods like TDDFT and EOM-CCSD, thereby enhancing photosensitizer performance [34, 3, 35]. The fusion of quantum computing with precision medicine holds promise for developing therapies tailored to glioma tumors' specific characteristics.

Nanotechnology's role in PDT is crucial for improving photosensitizer delivery and targeting, addressing issues like poor solubility and tissue penetration. Research on hydrophilic photosensitizers and longer wavelength lasers aims to enhance tissue penetration. Dual-functional aggregation-induced emission (AIE) nanoparticles, which produce ROS and serve as imaging agents, exemplify nanotechnology's potential to improve PDT's diagnostic and therapeutic aspects [33].

Advanced imaging techniques, such as multiscale super-resolution MRI, are integral to precision medicine, providing detailed tumor visualization and treatment response monitoring, thus enabling adaptive strategies tailored to individual responses [32]. The integration of PDT with precision medicine offers a comprehensive framework for improving glioma treatment by leveraging technologies like glioma-on-a-chip models and strategies targeting gliomas' unique genomic and metabolic features [9, 1, 4, 11, 10].

6.2 Innovative Technologies and Future Directions

Emerging technologies in precision medicine promise to revolutionize glioma treatment by targeting tumors' intricate metabolic and molecular characteristics. Exploring novel metabolic targets, such as glutamine metabolism, offers opportunities to disrupt glioma cells' metabolic dependencies [22]. Understanding these adaptations is crucial for identifying potential metabolic inhibitors as therapeutic agents [10], and future research should focus on developing combination therapies that integrate metabolic interventions with existing immunotherapies [24].

Lactylation's role in cancer metabolism is gaining attention, with potential implications for both cancer and inflammatory diseases. Elucidating lactylation mechanisms and identifying lactate metabolism biomarkers could significantly enhance therapeutic precision [23]. Combining PDT with other modalities, such as immunotherapy and targeted therapies, presents a promising strategy for improving outcomes [37].

Advancements in computational modeling, including evolutionary game theory, provide powerful tools for optimizing therapeutic strategies and understanding TME interactions [38]. These models can guide the development of adaptive systems that respond to evolving tumor biology, optimizing treatment protocols.

Nanotechnology integration in PDT remains a critical innovation area, enhancing targeting efficiency and reducing off-target effects. Folic acid-functionalized nanoparticles demonstrate potential for improving therapeutic delivery in glioma treatment [16]. Future research should optimize folic acid density and spacer use to maximize targeting efficiency.

The application of circRNAs in cancer therapy is an exciting frontier, with potential as therapeutic agents regulating key metabolic pathways [26]. Understanding circRNAs' role in metabolism could open new therapeutic avenues.

Optimizing temperature measurement techniques, like the Serum-Anisotropy Based Nanothermometer (Serum-ABNT), could have innovative applications in precision medicine for cancer treatment [5]. Enhancing capabilities to monitor and manipulate the TME holds promise for improving glioma therapy precision and efficacy.

Integrating these emerging technologies with precision medicine provides a comprehensive framework for advancing glioma treatment. By utilizing advancements in metabolic targeting, computational modeling, and nanotechnology, researchers can develop personalized strategies addressing gliomas' intricate biological mechanisms. These strategies aim to improve patient outcomes by targeting diverse metabolic pathways, including glucose metabolism and amino acid and fatty acid utilization. Innovative glioma-on-chip models facilitate in vivo simulation, enabling testing of therapeutic approaches and drug combinations, ultimately enhancing treatment efficacy and patient survival rates [4, 8, 1, 10].

7 Tumor Microenvironment and Its Impact

7.1 Tumor Microenvironment and Resistance Overcoming

The tumor microenvironment (TME) is crucial in mediating therapeutic resistance in gliomas, acting as a complex ecosystem that supports tumor survival and progression. Key components such as cancer-associated fibroblasts, immune cells, extracellular matrix elements, and signaling molecules collectively contribute to resistance against conventional therapies [9]. These elements interact with tumor cells to create a protective niche that facilitates immune evasion and treatment resilience.

Addressing resistance necessitates targeting specific TME elements that contribute to this protective environment, including metabolic reprogramming, the role of cancer-associated fibroblasts, and communication pathways between tumor cells and surrounding stroma. Disrupting these interactions can enhance therapeutic efficacy and potentially overcome the adaptive resistance mechanisms tumors develop [7, 30, 1, 9, 8]. For instance, targeting signaling pathways involved in tumor-stroma communication can disrupt feedback loops that sustain tumor growth.

Modulating the immune landscape within the TME is another promising strategy to overcome resistance. Reprogramming immune cells, such as shifting macrophages from an M2 to an M1 phenotype, can enhance anti-tumor immune responses and improve therapeutic outcomes. Additionally, targeting the metabolic dependencies of both tumor and immune cells can disrupt nutrient competition that favors tumor survival. Addressing metabolic interplay can limit essential nutrient availability for tumors while enhancing immune cell functionality, sensitizing tumors to treatments and mitigating immunosuppressive effects from tumor-derived metabolites [8, 24, 9, 39].

Innovative approaches that combine these strategies with advanced technologies, such as nanotechnology and precision medicine, hold potential for selectively targeting and modulating the TME. Integrating advanced therapeutic strategies with glioma-on-chip models can lead to more effective and personalized interventions, addressing tumor heterogeneity and resistance mechanisms to enhance treatment efficacy and improve patient survival outcomes [4, 1].

7.2 Metabolic Interactions and Immune Responses

The TME significantly influences cancer cell behavior and therapeutic response through metabolic interactions that shape immune responses [1]. Within the TME, cancer and immune cells engage in a complex interplay, competing for nutrients and modulating each other's functions. This metabolic competition impacts the immune landscape, often leading to immune suppression and facilitating tumor progression.

Altered metabolic pathways in cancer cells, such as enhanced glycolysis, result in the accumulation of byproducts like lactate, which supports tumor growth and creates an acidic microenvironment. This environment suppresses effector immune cell activity, including T cells and natural killer (NK) cells, diminishing the immune system's ability to mount an effective anti-tumor response [31, 8, 39, 28, 24].

Additionally, the TME influences immune cell polarization and function through metabolic cues. For example, macrophages can adopt pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes based on metabolic signals. The M2 phenotype, associated with immune suppression and tissue remodeling, promotes cancer progression. Thus, the metabolic reprogramming of macrophages within the TME critically influences their roles in tumor immunity, affecting tumor initiation, growth, and overall immune response [8, 24, 31].

Targeting metabolic pathways and immune responses within the TME is crucial for enhancing therapeutic efficacy. Strategies that disrupt the metabolic dependencies of cancer cells or reprogram immune cell metabolism may overcome immune evasion and improve treatment outcomes. By strategically altering metabolic dynamics in the TME, researchers can enhance the efficacy of current cancer therapies and develop innovative strategies that leverage the immune system to effectively target and eliminate cancer cells, addressing the complex interactions between tumor cells and stromal components [7, 9, 8, 39, 24].

7.3 Non-Cell-Autonomous Mechanisms of Tumor Resistance

Non-cell-autonomous mechanisms significantly mediate tumor resistance, particularly in gliomas, where the TME influences therapeutic outcomes. Resistance mechanisms are intricately linked to interactions between tumor cells and their surrounding environment, comprising stromal cells, including cancer-associated fibroblasts (CAFs), immune cells, and extracellular matrix elements. These interactions facilitate tumor progression and contribute to the adaptive resistance mechanisms that tumors develop against therapies like chemotherapy and radiotherapy [8, 30, 9, 29].

A primary non-cell-autonomous factor in tumor resistance is the presence of CAFs within the TME. CAFs secrete growth factors, cytokines, and extracellular matrix-remodeling enzymes that support tumor growth while modulating immune cell function to create an immunosuppressive environment [30]. This interaction promotes tumor proliferation and immune evasion, thereby reducing therapeutic efficacy [8].

Metabolic interactions within the TME also play a significant role in non-cell-autonomous resistance mechanisms. Tumor cells often exhibit altered metabolic pathways, producing metabolites like lactate that modulate the behavior of surrounding immune and stromal cells [23]. The accumulation of lactate can suppress effector immune cell activity and promote macrophage polarization towards a tumor-promoting M2 phenotype, further contributing to immune evasion and resistance [31].

Exosome-mediated communication within the TME is another critical non-cell-autonomous mechanism influencing tumor resistance. Tumor-derived exosomes can transfer proteins, lipids, and nucleic acids to recipient cells, modulating their behavior and fostering a pro-tumorigenic environment [7]. This exchange of molecular information between tumor and stromal cells enhances resistance to therapies by supporting tumor cell survival and adaptation.

To combat non-cell-autonomous resistance mechanisms, therapeutic strategies must focus on the intricate interactions within the TME that enhance tumor resilience. This includes targeting metabolic reprogramming, the influence of CAFs, and immune response regulation [30, 1, 9, 20, 8]. Approaches that disrupt supportive interactions between tumor cells and their microenvironment, such as targeting CAFs or modulating immune cell metabolism, hold promise for overcoming resistance and enhancing the efficacy of existing therapies. Leveraging insights into non-cell-autonomous resistance mechanisms may lead to more effective and personalized interventions for glioma patients.

8 Conclusion

Photodynamic therapy (PDT), when combined with an in-depth understanding of metabolic reprogramming and therapeutic resistance, offers a compelling approach to glioma treatment. Advances in xanthene dye technology have bolstered their integration into cancer imaging and treatment, offering enhanced properties. The strategic targeting of cytochrome c oxidase (COX) by Pt(II)-TMPyP, which induces mitochondrial damage and cell death upon light activation, underscores the importance of manipulating metabolic pathways to enhance PDT's effectiveness. Understanding the genomic features of resistant glioma stem cells is crucial for developing interventions aimed at reducing glioblastoma recurrence.

The tumor microenvironment (TME) plays a pivotal role in therapeutic outcomes, with its intricate interactions influencing tumor progression and resistance. Modulating components of the TME, such as cancer-associated fibroblasts and immune cells, holds promise for improving treatment efficacy. Future research should focus on incorporating immune responses into glioma-on-chip models and leveraging machine learning for data analysis to refine therapeutic predictions.

Additionally, PDT's potential is augmented by insights from quantum mechanics, which aid in refining glioma targeting strategies. Innovations in nanotechnology, including the development of novel photosensitizers and targeted delivery systems, further enhance PDT's clinical effectiveness. The creation of an integrated fiberoptic platform for cancer diagnosis, treatment, and monitoring highlights its superiority over traditional nanoparticle-based systems, offering a comprehensive approach to glioma management.

AI-generated, for reference only.

References

[1] Satoru Osuka, Erwin G Van Meir, et al. Overcoming therapeutic resistance in glioblastoma: the way forward. *The Journal of clinical investigation*, 127(2):415–426, 2017.

[2] G. Corbin, C. Engwer, A. Klar, J. Nieto, J. Soler, C. Surulescu, and M. Wenske. Modeling glioma invasion with anisotropy- and hypoxia-triggered motility enhancement: from subcellular dynamics to macroscopic pdes with multiple taxis, 2020.

[3] Anton Nykänen, Leander Thiessen, Elsi-Mari Borrelli, Vijay Krishna, Stefan Knecht, and Fabijan Pavošević. δadapt-vqe: Toward accurate calculation of excitation energies on quantum computers for bodipy molecules with application in photodynamic therapy, 2024.

[4] Merve Ustun, Sajjad Rahmani Dabbagh, Irem Sultan Ilci, Tugba Bagci-Onder, and Savas Tasoglu. Glioma-on-a-chip models. *Micromachines*, 12(5):490, 2021.

[5] Cristina Carrizo, Gianluca DÁgostino, Graham Spicer, Jaime Fernández de Córdoba, Rubén Ahijado Guzmán, Clara Maria Garcia-Abad, Aitor Rivas, Ruth Matesanz, Ana Oña, and Sebastian A. Thompson. Towards an innate cell-environment nanothermometer, 2024.

[6] José Pedro Friedmann Angeli, Dmitri V Krysko, and Marcus Conrad. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. *Nature Reviews Cancer*, 19(7):405–414, 2019.

[7] Enli Yang, Xuan Wang, Zhiyuan Gong, Miao Yu, Haiwei Wu, and Dongsheng Zhang. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. *Signal transduction and targeted therapy*, 5(1):242, 2020.

[8] Miguel Reina-Campos, Jorge Moscat, and Maria Diaz-Meco. Metabolism shapes the tumor microenvironment. *Current opinion in cell biology*, 48:47–53, 2017.

[9] Peijie Wu, Wei Gao, Miao Su, Edouard C Nice, Wenhui Zhang, Jie Lin, and Na Xie. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. *Frontiers in cell and developmental biology*, 9:641469, 2021.

[10] Marie Strickland and Elizabeth A Stoll. Metabolic reprogramming in glioma. *Frontiers in cell and developmental biology*, 5:43, 2017.

[11] Sue Han, Yang Liu, Sabrina J Cai, Mingyu Qian, Jianyi Ding, Mioara Larion, Mark R Gilbert, and Chunzhang Yang. Idh mutation in glioma: molecular mechanisms and potential therapeutic targets. *British journal of cancer*, 122(11):1580–1589, 2020.

[12] Adelina-Gabriela Niculescu and Alexandru Mihai Grumezescu. Photodynamic therapy—an up-to-date review. *Applied Sciences*, 11(8):3626, 2021.

[13] Hiromi Kataoka, Hirotada Nishie, Noriyuki Hayashi, Mamoru Tanaka, Akihiro Nomoto, Shigenobu Yano, and Takashi Joh. New photodynamic therapy with next-generation photosensitizers. *Annals of translational medicine*, 5(8):183, 2017.

[14] Osman Karaman, Gizem Atakan Alkan, Caglayan Kizilenis, Cevahir Ceren Akgul, and Gorkem Gunbas. Xanthene dyes for cancer imaging and treatment: A material odyssey, 2022.

[15] Wenqi Jiang, Mingkang Liang, Qifang Lei, Guangzhi Li, and Song Wu. The current status of photodynamic therapy in cancer treatment. *Cancers*, 15(3):585, 2023.

[16] Edoardo Donadoni, Paulo Siani, Giulia Frigerio, and Cristiana Di Valentin. Multi-scale modeling of folic acid-functionalized tio_2 nanoparticles for active targeting of tumor cells, 2022.

[17] Gurcan Gunaydin, M Emre Gedik, and Seylan Ayan. Photodynamic therapy—current limitations and novel approaches. *Frontiers in Chemistry*, 9:691697, 2021.

[18] Jian Wei Tay, Puxiang Lai, Yuta Suzuki, and Lihong V. Wang. Digital ultrasonically encoded (due) optical focusing into random media, 2013.

[19] Conor C. Horgan, Mads S. Bergholt, Anika Nagelkerke, May Zaw Thin, Isaac J. Pence, Ulrike Kauscher, Tammy L. Kalber, Daniel J. Stuckey, and Molly M. Stevens. Integrated photodynamic raman theranostics for cancer diagnosis, treatment, and post-treatment molecular monitoring, 2020.

[20] Andrea Morandi and Stefano Indraccolo. Linking metabolic reprogramming to therapy resistance in cancer. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1868(1):1–6, 2017.

[21] Ruby Kuang, Arman Jahangiri, Smita Mascharak, Alan Nguyen, Ankush Chandra, Patrick M Flanigan, Garima Yagnik, Jeffrey R Wagner, Michael De Lay, Diego Carrera, et al. Glut3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. *JCI insight*, 2(2):e88815, 2017.

[22] R e v i e w a r t i c l e.

[23] An-Na Chen, Yan Luo, Yu-Han Yang, Jian-Tao Fu, Xiu-Mei Geng, Jun-Ping Shi, and Jin Yang. Lactylation, a novel metabolic reprogramming code: current status and prospects. *Frontiers in immunology*, 12:688910, 2021.

[24] Longzheng Xia, Linda Oyang, Jinguan Lin, Shiming Tan, Yaqian Han, Nayiyuan Wu, Pin Yi, Lu Tang, Qing Pan, Shan Rao, et al. The cancer metabolic reprogramming and immune response. *Molecular cancer*, 20:1–21, 2021.

[25] Shivani K Thaker, James Ch'ng, and Heather R Christofk. Viral hijacking of cellular metabolism. *BMC biology*, 17:1–15, 2019.

[26] Tao Yu, Yanfen Wang, Yu Fan, Na Fang, Tongshan Wang, Tongpeng Xu, and Yongqian Shu. Circrnas in cancer metabolism: a review. *Journal of hematology & oncology*, 12:1–10, 2019.

[27] Chelsea Schiliro and Bonnie L Firestein. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. *Cells*, 10(5):1056, 2021.

[28] Kenji Ohshima and Eiichi Morii. Metabolic reprogramming of cancer cells during tumor progression and metastasis. *Metabolites*, 11(1):28, 2021.

[29] Eishu Hirata and Erik Sahai. Tumor microenvironment and differential responses to therapy. *Cold Spring Harbor perspectives in medicine*, 7(7):a026781, 2017.

[30] Micol Eleonora Fiori, Simone Di Franco, Lidia Villanova, Paola Bianca, Giorgio Stassi, and Ruggero De Maria. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of emt and therapy resistance. *Molecular cancer*, 18:1–16, 2019.

[31] Yang Liu, Ruyi Xu, Huiyao Gu, Enfan Zhang, Jianwei Qu, Wen Cao, Xi Huang, Haimeng Yan, Jingsong He, and Zhen Cai. Metabolic reprogramming in macrophage responses. *Biomarker Research*, 9:1–17, 2021.

[32] Siyuan Dong, Gilbert Hangel, Wolfgang Bogner, Georg Widhalm, Karl Rössler, Siegfried Trattnig, Chenyu You, Robin de Graaf, John Onofrey, and James Duncan. Multi-scale super-resolution magnetic resonance spectroscopic imaging with adjustable sharpness, 2022.

[33] Xianhe Sun, Abudureheman zebibula, Xiaobiao Dong, Gonghui Li, Guanxin Zhang, Deqing Zhang, Jun Qian, and Sailing He. Targeted and imaging-guided in vivo photodynamic therapy of tumors using dual-functional, aggregation-induced emission nanoparticles, 2017.

[34] Vincent M. Rossi. A quantum mechanical description of photosensitization in photodynamic therapy using a two-electron molecule approximation, 2023.

[35] Michael Boersch. Targeting cytochrome c oxidase in mitochondria with pt(ii)-porphyrins for photodynamic therapy, 2010.

[36] Ruben V Huis in 't Veld, Jeroen Heuts, Sen Ma, Luis J Cruz, Ferry A Ossendorp, and Martine J Jager. Current challenges and opportunities of photodynamic therapy against cancer. *Pharmaceutics*, 15(2):330, 2023.

[37] <div style="text-align: center;".

[38] David Basanta, Matthias Simon, Haralambos Hatzikirou, and Andreas Deutsch. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion, 2008.

[39] Kathrin Renner, Katrin Singer, Gudrun E Koehl, Edward K Geissler, Katrin Peter, Peter J Siska, and Marina Kreutz. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. *Frontiers in immunology*, 8:248, 2017.

[40] Michael A Reid, Ziwei Dai, and Jason W Locasale. The impact of cellular metabolism on chromatin dynamics and epigenetics. *Nature cell biology*, 19(11):1298–1306, 2017.

AI-generated, for reference only.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.

AI-generated, for reference only.